Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: patlawche11 who wrote (50140)	2/8/2019 6:26:30 AM
From: li3511	2 Recommendations Recommended By idahoranch1 patlawche11 Respond to of 63285

> wouldn't IMMU have a sense of whether or not 132 was showing improved efficacy over the control (maybe not with full statistical analysis) well ahead of 2020 Not necessarily. The trial is being run by a CRO, and it’s unlikely that the day-by-day results are known beyond the DSMB. Also, there is unlikely to be an interim data analysis in order to provide maximum power to the trial at its conclusion. The efficacy of IMMU-132 is already well enough known to preclude overwhelming evidence of efficacy (or overwhelming evidence of futility) midstream.